Skip to main content
. 2018 Jan 11;14(1):47–56. doi: 10.7150/ijbs.22209

Figure 4.

Figure 4

Low SHP2-expressing tumors may be associated with unfavorable response and poor overall survival in patients with lung adenocarcinoma who have received TKI therapy when compared to patients with high SHP2-expressing tumors. (a) SHP2 mRNA expression levels were significantly higher in patients with an unfavorable response than in patients with a favorable response to TKI. (b) Kaplan-Meier analysis was used to estimate prognosis in patients with high SHP2-expressing tumors to have poorer overall survival than in patients with low SHP2-expressing tumors.